Schr'dinger is transforming the way therapeutics and materials are discovered. Schr'dinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Founded in 1990, Schr'dinger has over 700 employees and is engaged with customers and collaborators in more than 70 countries.